As the oldest person elected president of the United States, Donald Trump has long faced questions about his health. But is it appropriate for doctors to comment publicly on a president’s mental health? In an opinion article published by The BMJ today, David Nicholl and Trisha Greenhalgh examine the ethical tensions involved. While heads of state are entitled to medical confidentiality, their decisions can have far-reaching consequences, raising the question of whether professional norms against public commentary should ever be set aside.

Exclusive data published by The BMJ today show that 13,386 patients in England waited at least three days for A&E treatment last year, part of almost 500,000 who spent over 24 hours stuck in NHS emergency departments - before either being admitted, transferred, or discharged - in 2025.

Critical Path Institute’s® Critical Path for Alpha-1 Antitrypsin Deficiency Consortium today announced the addition of AIRNA as its newest industry partner, bringing RNA editing expertise to the consortium’s efforts to accelerate drug development for alpha-1 antitrypsin deficiency (AATD). AIRNA joins existing industry members CSL Behring, Sanofi, Takeda, and Beam Therapeutics, as well as a coalition of academic clinician researchers, patient advocacy groups, and regulatory colleagues working collaboratively to advance regulatory-endorsed drug development solutions for patients living with AATD.

Treatment with GMRx2, a single pill combination of three low-dose blood pressure medicines, significantly reduced the risk of another stroke in patients with intracerebral haemorrhage and high blood pressure. Results from the TRIDENT randomised controlled trial, led by The George Institute for Global Health, were published today in The New England Journal of Medicine.

For people who see a neurology clinician for the first time, a new study has found that being seen virtually vs. in-person made no difference in how soon they needed more care. The study was published April 22, 2026, in Neurology^®, the medical journal of the American Academy of Neurology.

The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving these advances, with new research spanning oncology, cardiology and neurosciences, innovations in imaging equipment and instrumentation, and real‑world clinical applications that are reshaping how diseases are diagnosed, treated, and monitored.